6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS
    1.
    发明申请
    6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS 审中-公开
    用于治疗CNS疾病的6-环丙基 - 吡唑并嘧啶酮

    公开(公告)号:US20130040971A1

    公开(公告)日:2013-02-14

    申请号:US13369623

    申请日:2012-02-09

    CPC分类号: C07D487/04

    摘要: The invention relates to novel pyrazolopyrimidinones according to formula (I) wherein R1 is a pyridyl or pyrimidinyl group and D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

    摘要翻译: 本发明涉及式(I)的新型吡唑并嘧啶酮,其中R 1为吡啶基或嘧啶基,D为任选取代的环戊基,环己基,四氢呋喃基,四氢吡喃基或2-,3-或4-吡啶基。 这些新化合物分别用作药物的活性成分或药物的制造,特别是用于治疗感知,集中,学习或记忆缺陷的病症的药物。 这种情况可能例如与阿尔茨海默病,精神分裂症和其他疾病相关。 新化合物还例如用于制备药物和/或用于治疗这些疾病,特别是与这种疾病相关的认知障碍。 本发明化合物显示PDE9抑制性质。

    6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS
    2.
    发明申请
    6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS 审中-公开
    用于治疗CNS疾病的6-环丙基 - 吡唑并嘧啶酮

    公开(公告)号:US20150025088A1

    公开(公告)日:2015-01-22

    申请号:US14511238

    申请日:2014-10-10

    IPC分类号: C07D487/04

    摘要: The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2.The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

    摘要翻译: 本发明涉及式(I)的新型6-环烷基 - 吡唑并嘧啶酮。 其中R1是5或6元芳族杂芳基,R2是任选的取代基,D是任选取代的环戊基,环己基,四氢呋喃基,四氢吡喃基或2-,3-或4-吡啶基,m = 1或2,n是0 ,1或2.新化合物分别用作药物的活性成分或用于制造药物,特别是用于治疗感知,集中,学习或记忆缺陷的病症的药物。 这种情况可能例如与阿尔茨海默病,精神分裂症和其他疾病相关。 新化合物还例如用于制备药物和/或用于治疗这些疾病,特别是与这种疾病相关的认知障碍。 本发明化合物显示PDE9抑制性质。

    6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS
    6.
    发明申请
    6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS 有权
    用于治疗CNS疾病的6-环丙基 - 吡唑并嘧啶酮

    公开(公告)号:US20130040955A1

    公开(公告)日:2013-02-14

    申请号:US13369596

    申请日:2012-02-09

    CPC分类号: C07D487/04 C07D519/00

    摘要: The invention relates to novel pyrazolopyrimidinones according to formula (I). wherein X is CRe or unsubstituted N, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, Ra, Rb, Rc, Rd, Re are either H or optional substituents, m=1 or 2 and n is 0, 1 or 2.The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

    摘要翻译: 本发明涉及式(I)的新型吡唑并嘧啶酮。 其中X为CRe或未取代的N,D为任选取代的环戊基,环己基,四氢呋喃基,四氢吡喃基或2-,3-或4-吡啶基,Ra,Rb,Rc,Rd,Re为H或任选的取代基,m = 1或 2和n为0,1或2.新化合物分别用作药物的活性成分或用于制备药物,特别是用于治疗有关感知,集中,学习或记忆缺陷的病症的药物。 这种情况可能例如与阿尔茨海默病,精神分裂症和其他疾病相关。 新化合物还例如用于制备药物和/或用于治疗这些疾病,特别是与这种疾病相关的认知障碍。 本发明化合物显示PDE9抑制性质。

    COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
    7.
    发明申请
    COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS 审中-公开
    化合物治疗CNS病症

    公开(公告)号:US20140350025A1

    公开(公告)日:2014-11-27

    申请号:US14087035

    申请日:2013-11-22

    IPC分类号: C07D487/04

    CPC分类号: C07D487/04 A61K31/519

    摘要: The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R1 is the group V—W—*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted.According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.

    摘要翻译: 本发明涉及式(I)的新颖的1,6-二取代吡唑并嘧啶酮,其中Hc是四氢吡喃基,R1是V-W- *,其中V和W彼此独立地可以是芳基或 彼此独立地可以任选地被取代的杂芳基。 根据本发明的一个方面,新化合物用作药物或用于制备药物,特别是用于治疗有关感知,集中,学习或记忆缺陷的病症的药物。 新化合物也用于制备药物和/或用于治疗例如药物。 阿尔茨海默病,特别是与阿尔茨海默病相关的认知障碍。